International Speakers - Radiation Oncology

Chris Crane

Dr Chris Crane

Christopher Crane, MD, is Vice Chairman and Gastrointestinal Section Leader in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He also serves as Chair of the Non-colorectal subcommittee of NRG Oncology. He is an internationally recognized expert in the in the treatment of gastrointestinal malignancies. He is currently focused on the developing ablative radiation strategies in the curative treatment of liver and pancreatic cancers. He has pioneered techniques to address organ motion management challenges by incorporating image guidance and adaptive treatment planning using universally available technologies. He is also involved in defining the future role of MRI image guidance and that will make these complex techniques more readily available. He has also conducted clinical trials in pancreatic, liver, anal, and rectal cancers focusing on the combination of molecular targeted therapies with radiotherapy as well as correlative studies focused on the development of predictive markers.

 

Sean Collins

Associate Professor Sean Collins

Sean Collins, MD, PhD, joined his twin brother Brian on the faculty of the cancer center in July of 2006 as an attending physician in radiation oncology. He graduated from the MSTP Program at the University of Michigan in 2001. Dr. Collins completed both an internship in surgery and a residency in radiation oncology at Georgetown University Hospital. His area of expertise is prostate cancer, for which he treats patients using the CyberKnife, a technology that allows for more accurate targeting of radiation therapy. Dr. Collins is a physician-scientist which means he conducts clinical and laboratory research. The focus of his clinical work is to develop prostate cancer treatment protocols using stereotactic body radiation therapy (SBRT) to minimizing the toxicity of radiation dose escalation. To date he has treated over 1300 prostate cancer patients with SBRT and has presented his work at major meeting and published multiple papers on his experience in peer reviewed journals.

 

Heiko Enderling

Associate Professor Heiko Enderling

Heiko Enderling, PhD, is Associate Professor of Integrated Mathematical Oncology and Radiation Oncology at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He also serves as the Director for Education and Outreach in the Moffitt Physical Sciences in Oncology Center and on the Board of Directors of the Society for Mathematical Oncology. He directs a research group on Quantitative Personalized Oncology with the aim to integrate mathematical, biological and clinical science to simulate tumor growth and forecast treatment response for individual patients.

Dr. Enderling graduated with an applied computer engineering degree from the University of Magdeburg, Germany, in 2003, and completed his PhD in Mathematical Biology at the University of Dundee, Scotland, in 2006. His work focusses on using pre-treatment tumor growth dynamics to identify optimal radiation dose and dose fractionation for individual patients, and to evaluate tumor response data for adaptive therapy. Additionally, his work evaluates synergy of radiation with systemic agents including immunotherapy for improved patient responses and treatment outcomes.

  

Dr. Surbhi Grover
Dr Surbhi Grover

Dr. Surbhi Grover is an Assistant Professor of Radiation Oncology at University of Pennsylvania and Adjunct Senior Lecturer at University of Botswana. She is interested in addressing the growing global cancer burden by focusing on public health endeavors and cost-effective clinical initiatives to improve access to care and outcomes of care in developing countries. Since 2011, she has been working with the Botswana-UPENN partnership, strengthening the oncology program in Botswana. She moved full-time to Botswana in 2014. In her current role at the Princess Marina Hospital, she is seeing cancer patients at the public hospital, conducting research and teaching at the University of Botswana School of Medicine. She is leading the implementation of an ongoing U54-funded study focused on cervical cancer and is involved with mentoring several junior investigators at the University of Botswana through the mentoring core of U54. She has lead the development of the first gynecological cancers multi-disciplinary tumor board in Botswana and is currently working on building a similar tumor board for head and neck cancer patients and breast cancer patients as well. She is leading the radiation oncology training platform for AORTIC, African body on cancer research and training. She has authored over 95 publications and has lead and been involved in several grants focusing on cancer care in low and middle income countries.

 

Bruce Minsky

Professor Bruce Minsky - ASTRO Representative

Bruce D. Minsky, MD, is Professor and Director of Clinical Research of the Division of Radiation Oncology at the MD Anderson Cancer Center. He is an active clinician and clinical research investigator on the Gastrointestinal Cancer multi-disciplinary team. He holds the Frank T. McGraw Memorial Chair for the Study of Cancer.

Dr. Minsky received his medical degree from the University of Massachusetts in 1982. He was a Medical Intern at New England Deaconess Hospital and completed his residency in radiation therapy at the Harvard Joint Center for Radiation Therapy. Following completion of his residency in 1986 Dr. Minsky spent the first 20 years of his career at Memorial Sloan Kettering Cancer Center as a clinician and clinical research investigator in Gastrointestinal Cancer. While at MSKCC, he was also the Vice Chair of Radiation Oncology from 2000-2007 and achieved the rank of Professor of Radiation Oncology at Cornell University in 1999. In 2004, he received a medical degree honoris causa from Friedrich Alexander University, Erlangen, Germany in recognition for his work in gastrointestinal cancers. He received the MSKCC Distinguished Alumni Award in 2008. From 2007 to 2012 Dr. Minsky served as a Professor of Radiation and Cellular Oncology and Associate Dean in the Biological Sciences Division at the University of Chicago. During that time he was also the Chief Quality Officer at the University of Chicago Medical Center.

Dr. Minsky is an editorial board member of several journals and has lectured and published widely. He is the co-chair of the NCI Gastrointestinal Steering Committee and has served on the board of directors for both the ASTRO and ASCO. He was the 2015 ASTRO President, elected an honorary member of ESTRO in 2014, and became a Fellow of ASCO (FASCO) in 2018.

 

Birgitte Offersen

Professor Birgitte Offersen

Professor Offersen is the head of the Danish Breast Cancer Group (DBCG) Radiotherapy Committee and a member of the DBCG Board. She is the Breast Editor on the Radiotherapy & Oncology, and a member of several IDMCs for randomized trials. Since 2009, she has been a teacher on ESTRO’s (European Society for Radiotherapy & Oncology) courses on Multidisciplinary Management of Breast Cancer, Partial Breast Radiotherapy, and the Online Breast Contouring. As part of the latter, she was leading an ESTRO Consensus Guideline on Target Volume Delineation in Early Breast Cancer, which has become the standard in most European radiotherapy centres.

She graduated from Aarhus University in 1995. In 2002, she completed her PhD on tumour microenvironment. In 2007, she specialised as a clinical oncologist and subsequently developed an interest in breast cancer radiotherapy. In 2009, she initiated the DBCG HYPO and DBCG PBI randomized trials where a dose of 40 Gy in15 fractions was tested both in relation to 50 Gy in 25 fractions (HYPO trial) and to whole breast irradiation versus partial breast irradiation (PBI trial). The outcomes from these trials have led to new national standards in the practice of Radiation Oncology in Denmark. Professor Offersen is also the principal investigator on the randomized Skagen trial 1 investigating loco-regional radiotherapy comparing doses of 50 Gy in 25 fractions and 40 Gy in15 fractions. This trial is currently active in nine countries. Later this year, further two randomized trials – with Professor Offersen as the principal investigator – will open for accrual: the DBCG RT Recon trial testing loco-regional postmastectomy radiotherapy following breast reconstruction, and the DBCG RT Natural trial evaluating omission of adjuvant radiotherapy.

 

Dr Bradley Pieters - ESTRO Representative

Bradley R. Pieters, MD, PhD, is Head of the Brachytherapy department at the Amsterdam University Medical Centers, location AMC, The Netherlands. Dr. Pieters is the chair of the GEC-ESTRO and Course Director of the ESTRO Comprehensive and Practical Brachytherapy course. Dr. Pieters was trained in Radiation Oncology at the Radboud University Hospital in Nijmegen, The Netherlands, and received his medical degree in 1990. He completed his residency in radiotherapy at Academic Hospital Nijmegen, The Netherlands. Dr. Pieters then completed a brachytherapy fellowship at the Daniel den Hoed clinic in Rotterdam and L'Institut Gustav-Roussy in Villejuif, France. His brachytherapy training was completed at the Academic Medical Center in Amsterdam. Dr. Pieters received his MSc in epidemiology in 2006 and his PhD in 2010 after defending his thesis “Pulsed-dose rate brachytherapy in prostate cancer.” Dr. Pieters’ main field of interest is general brachytherapy with an emphasis on urologic brachytherapy, gynecologic brachytherapy, and pediatric brachytherapy.

Dr. Pieters is currently one of the Principal Investigators of the PROBACH trial (Randomized Phase 3 Study on the Assessment of Late Toxicity by Comparing IMRT High Dose External Beam Radiotherapy Only With External Beam Radiotherapy Combined With HDR or PDR Brachytherapy in Patients With Intermediate/High Risk Prostate Cancer) and the POWER trial (Randomized trial for the evaluation of erectile dysfunction after whole or partial gland prostate brachytherapy). He is also working on the following research projects: multimodality dose summation assessment and evaluation for cervical cancer; ICT-based innovations in the battle against cancer – next-generation patient-tailored brachytherapy cancer treatment planning.

 

Yang Wang1   ICONGROUP CMYK Logo
Professor Yang Wang

Yang Wang, PhD, Director of Medical Physics (China)

Yang is also an academic teacher at the University of Wollongong in New South Wales Sydney.

Originally from Beijing China, Yang used to work at Beijing Railway General Hospital (from 1973 to 1987) and was one of the first generation of clinical physicists in China. In 1984 he was the lead clinical physicist in the commissioning of the first Varian linear accelerator in China.

Yang came to study in Australia in 1987. In 1990 he commenced at Sydney St Vincent’s Hospital Radiotherapy Department as a medical physicist. From 2006 to 2013 Yang was the Director of Medical Physics for Genesis Cancer Care and he joined Radiation Oncology Institute Sydney (now known as ICON-ROC) as Director Medical Physics of NSW in 2014.

In 1997 Yang obtained MSc of Engineering from Macquarie University Sydney, and in 2005 he obtained a PhD in Medical Physics from University of Wollongong (UOW). In the same year he started work as a lecturer in a teaching fellowship for UOW, and by 2012 he accepted the Principal Teaching Fellowship from UOW.